Peptide Programs in 2026: A Safety and Compliance Checklist for Clinics

Peptide therapy continues to attract interest from med spas, aesthetic clinics, telehealth providers, and wellness practices. But a successful peptide program requires more than a popular treatment menu and a prescribing workflow.

In 2026, clinics must be prepared to show that their program is clinically appropriate, properly supervised, supported by reliable pharmacy partners, and responsive to changing FDA requirements.

This checklist can help your clinic build a safer and more defensible peptide program.

Important: This article is for general educational purposes. It is not legal advice or a substitute for guidance from qualified healthcare, pharmacy, regulatory, and legal professionals. Requirements may vary by state and by product.

1. Create written protocols before treating patients

A peptide program should begin with written protocols: not informal staff instructions or a questionnaire alone.

Your protocols should define:

• Which conditions and patient populations the clinic may treat
• Which products and routes of administration are permitted
• Inclusion and exclusion criteria
• Required medical history and physical examination elements
• Baseline and follow-up laboratory testing
• Dosing and titration procedures
• Patient education requirements
• Adverse-event documentation
• Escalation and referral procedures
• Prescription, dispensing, administration, and refill workflows
• Storage, handling, and disposal requirements

Protocols should be reviewed regularly by the clinic’s medical director and updated when FDA guidance, state rules, product availability, or pharmacy policies change.

A written protocol also helps ensure that every patient receives a consistent standard of care, regardless of which provider conducts the visit.

2. Establish meaningful medical director oversight

Medical director involvement should be active, documented, and appropriate to the clinic’s model.

The medical director should help approve:

• Clinical protocols and standing procedures
• Product selection and pharmacy relationships
• Patient screening criteria
• Laboratory requirements
• Informed-consent materials
• Emergency plans
• Staff training
• Quality-assurance reviews
• Advertising and patient-facing claims

Oversight should not be limited to signing documents. The medical director should review outcomes, adverse events, prescribing patterns, and protocol exceptions.

For multi-provider or telehealth practices, define when a case requires escalation to the medical director or another qualified clinician. Examples may include complex medical histories, abnormal baseline labs, significant adverse effects, rapid dose escalation requests, or uncertainty about whether a compounded product is clinically appropriate.

3. Require a good faith examination

A patient intake form can collect useful information, but it is not a substitute for a good faith examination.

Before prescribing, the clinician should obtain and document enough information to make an individualized clinical decision. Depending on the therapy and patient, this may include:

• Relevant medical and surgical history
• Current medications and supplements
• Allergies and prior reactions
• Diagnosis and treatment goals
• Previous use of the medication or related therapies
• Contraindications and precautions
• Pregnancy or reproductive considerations when relevant
• Recent vital signs and other examination findings
• Review of current symptoms and red flags
• Access to prior medical records when needed

For telehealth programs, define how the examination is performed, what information is verified, and when an in-person evaluation is necessary.

A questionnaire-only model is a red flag. It may create clinical risk and make it difficult to demonstrate that each prescription was based on an individualized assessment.

4. Obtain baseline labs and create a monitoring plan

Laboratory requirements should match the medication, route, patient risk factors, and treatment goals. There is no single lab panel that is appropriate for every peptide program.

Depending on the therapy, baseline testing may include:

• Comprehensive metabolic panel
• Kidney and liver function
• Fasting glucose or A1C
• Lipid profile
• Complete blood count
• Thyroid testing when clinically indicated
• Pregnancy testing when appropriate
• Other hormone or disease-specific testing

The protocol should specify when labs must be repeated and what results require a dose change, treatment pause, referral, or urgent evaluation.

Ongoing monitoring should include more than lab values. Track symptoms, adherence, weight or other treatment outcomes, dose changes, patient-reported adverse effects, and any emergency or urgent-care visits.

For GLP-1 therapies in particular, ensure patients understand how to measure doses accurately. FDA has reported dosing errors, including errors involving concentration, syringe measurements, titration schedules, and doses beyond approved labeling.

5. Use clear informed consent

Patients should understand what they are receiving before treatment begins.

Consent materials should explain:

• The treatment’s intended purpose
• Whether the product is FDA-approved or compounded
• Known and potential risks
• Common and serious adverse effects
• Expected benefits and limitations
• Alternatives, including FDA-approved therapies when appropriate
• Dosing and titration instructions
• Storage and transportation requirements
• When to contact the clinic
• When to seek emergency care
• The process for reporting quality concerns or adverse events

Avoid marketing language that suggests a compounded product is “the same as” an FDA-approved product, a generic equivalent, or clinically proven in the same way as an approved drug. FDA has specifically warned against these types of claims for non-FDA-approved compounded GLP-1 products.

Consent should be updated when the clinic changes the product, route, concentration, dosing schedule, or intended use.

6. Verify the pharmacy and source of every product

A clinic should source compounded medications only through an appropriate state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, consistent with the prescription, state law, and the product’s legal requirements.

Do not rely on a sales representative’s statement that a facility is “FDA approved.” FDA registers outsourcing facilities; it does not approve compounded drugs in the same manner as approved drug products.

Before onboarding a pharmacy partner, verify:

• Current state pharmacy licenses
• Current FDA 503B registration, if applicable
• Facility name and physical address
• Inspection and regulatory history
• Product and lot traceability
• Recall and complaint procedures
• Shipping and temperature-control processes
• Labeling and beyond-use-date practices
• Availability of pharmacy consultation
• Quality documentation for ingredients and finished products

FDA maintains a current list of registered outsourcing facilities. Clinics should recheck the list and applicable state licensing information periodically.

7. Understand bulk-substance and Category 1 status

“Category 1” does not mean that every peptide is approved, safe, or automatically available for every type of compounding.

For 503A compounding, FDA’s Category 1 list identifies bulk drug substances under evaluation. These substances may receive interim enforcement discretion when the applicable conditions are met, but the status can change. The list should be reviewed for the specific substance, dosage form, and route of administration.

For example, FDA’s May 14, 2026 update identifies GHK-Cu except for injectable routes of administration in Category 1. That does not establish eligibility for injectable GHK-Cu. The same FDA list also identifies some substances in Category 2 because of significant safety concerns.

Clinics should:

• Check the current FDA list before adding a peptide
• Confirm the exact substance, salt, form, route, and strength
• Verify whether the product is being compounded under 503A or 503B
• Confirm that the pharmacy has documented the legal basis for compounding
• Avoid assuming that a substance’s presence in Category 1 is final approval

For 503B outsourcing facilities, bulk drug substances generally must appear on the FDA 503B bulks list or be used when the compounded drug appears on the FDA drug shortage list at the time of compounding, distribution, and dispensing. A 503A Category 1 listing does not automatically authorize bulk use by a 503B facility.

8. Require certificates of analysis and quality records

A certificate of analysis, or COA, should be part of the pharmacy’s quality documentation: not a substitute for due diligence.

FDA states that bulk drug substances used by 503B facilities must be accompanied by a valid COA and manufactured by an FDA-registered establishment. If a USP or National Formulary monograph applies, the substance must comply with it.

Ask your pharmacy partner how it verifies:

• Identity
• Potency or assay
• Purity
• Impurities and contaminants
• Sterility, when applicable
• Endotoxins, when applicable
• Lot number and expiration information
• Supplier qualification
• Finished-product release testing

For sterile preparations, 503A pharmacies should follow applicable state requirements and USP <797> standards. USP <797> describes minimum standards for preparing compounded sterile preparations for human and animal drugs.

503B facilities are subject to federal requirements that include current good manufacturing practice. Clinics should not assume that a 503B facility’s registration alone proves that every product is appropriate. Review the facility’s quality systems, inspection history, testing practices, and product-specific documentation.

9. Address GLP-1 shortage and enforcement risk

GLP-1 products require special attention in 2026.

FDA determined that the tirzepatide injection shortage was resolved in December 2024 and the semaglutide injection shortage was resolved in February 2025. The related shortage-based enforcement-discretion periods ended in 2025.

As of FDA’s April 1, 2026 update, semaglutide and tirzepatide did not appear on the 503B bulks list or the FDA drug shortage list. Clinics should not build a program around the assumption that shortage-based compounding flexibility remains available.

FDA has also warned about:

• Semaglutide salt forms, including semaglutide sodium and semaglutide acetate
• Research-use-only products sold for human use
• Dosing errors and excessive titration
• Products arriving warm or inadequately refrigerated
• Fraudulent labels and pharmacies
• Retatrutide and cagrilintide, which FDA states cannot be used in compounding under federal law

Review the FDA’s current GLP-1 safety information and compounding policy update before offering or continuing a GLP-1 program.

10. Prepare for emergencies and quality complaints

Every clinic should have a written response plan for:

• Suspected allergic reactions
• Severe or persistent vomiting and diarrhea
• Dehydration
• Severe abdominal pain
• Medication errors
• Incorrect concentration or dose
• Temperature excursions during shipping
• Suspected contamination
• Product mix-ups
• Adverse events requiring emergency evaluation

Patients should receive clear after-hours instructions and know when to call emergency services rather than waiting for a clinic response.

Clinics should also maintain a process for documenting and reporting complaints, quarantining questionable product, contacting the pharmacy, notifying affected patients, and supporting recalls or investigations.

Red flags your clinic should avoid

Do not build a peptide program around:

• Research-grade peptides or products labeled “not for human consumption”
• Questionnaire-only prescribing
• Prescriptions without a documented clinical evaluation
• Unverified online suppliers
• Bulk office stock sourced from a 503A patient-specific pharmacy
• Products with no lot number, expiration date, or pharmacy information
• Missing or unverifiable COAs
• Marketing that calls compounded drugs “generic” or “identical”
• Unapproved salt forms or experimental peptides
• Dosing instructions that are unclear or inconsistent with the prescription
• Shipping practices that do not protect temperature-sensitive products

Build your program with the right pharmacy partner

A compliant peptide program depends on coordination between the clinic, prescribing team, medical director, and pharmacy.

One Pharmacy works with healthcare providers and wellness-focused practices to support organized prescription workflows, medication sourcing, patient education, and quality-focused compounding processes. Our team can help your clinic ask the right questions about pharmacy licensing, product documentation, sterile preparation, certificates of analysis, and changing FDA requirements.

Planning or reviewing a peptide program in 2026? Contact One Pharmacy to discuss how we can support your clinic’s safety and compliance goals.

Regulatory resources

• FDA: Bulk Drug Substances Used in Compounding Under Section 503B
• FDA: 503A Bulk Drug Substances, updated May 14, 2026
• FDA: Registered Outsourcing Facilities
• FDA: GLP-1 Safety Concerns
• FDA: Policies for Compounders as GLP-1 Supply Stabilizes
• USP <797>: Pharmaceutical Compounding: Sterile Preparations